Crucell, GlaxoSmithKline Biologicals To Jointly Develop Malaria Vaccine
The pre-clinical data from earlier studies indicated enhanced immune responses against the malaria parasite (circumsporozoite stage of the Plasmodium falciparum) when Crucell’s Adenovirus (AdVac) technology and GSK’s RTS,S/AS
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.